☆ 4.7 Article

Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future Direction

ONCOLOGIST (2023)

Related references

Note: Only part of the references are listed.

Article Critical Care Medicine

Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism A Randomized Trial

Benjamin Planquette et al.

Summary: This study compared the efficacy and safety of rivaroxaban and dalteparin in the treatment of cancer-associated VTE. The results showed that the efficacy and safety of rivaroxaban and dalteparin were consistent with those previously reported with DOACs.

CHEST (2022)

Add to Collection

Article Hematology

A proposal for managing bleeding in patients on therapeutic factor XI(a) inhibitors

Ophira Salomon et al.

Summary: Therapeutic inhibitors targeting FXI(a) are being evaluated as potential treatments for preventing thrombosis, with the expectation of having a smaller impact on hemostasis than current anticoagulants targeting thrombin or factor Xa. However, some patients on these inhibitors may still experience abnormal bleeding or require emergent surgery, necessitating the development of strategies to address these situations. Treatment with antifibrinolytic agents and low doses of recombinant factor VIIa has been effective in preventing abnormal bleeding in FXI-deficient patients, suggesting a potential strategy for patients on therapeutic FXI(a) inhibitors experiencing bleeding or requiring invasive procedures.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa

Byungdoo A. Yi et al.

Summary: Abelacimab, a novel fully human monoclonal antibody targeting Factor XI, demonstrates dual activity against the inactive and activated FXI. Studies show that abelacimab effectively reduces free FXI levels after intravenous and subcutaneous administration, with a favorable safety profile, supporting its clinical development.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Review Oncology

Practical treatment guidance for cancer-associated thrombosis-Managing the challenging patient: A consensus statement

Kathryn M. Musgrave et al.

Summary: Cancer-associated thrombosis (CAT) is a major cause of death in cancer patients. To aid healthcare professionals in decision-making, an expert working group developed consensus recommendations based on challenging clinical problems related to CAT.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection

Article Hematology

Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer

Tzu-Fei Wang

Summary: This paper reviews the existing evidence and guidelines on drug-drug interactions (DDIs) with anticoagulants, with a focus on the cancer population. It emphasizes the importance of anticoagulant therapy for cancer patients and highlights the potential impact of drug interactions on treatment efficacy and safety.

THROMBOSIS RESEARCH (2022)

Add to Collection

Article Medicine, General & Internal

Milvexian for the Prevention of Venous Thromboembolism

Jeffrey Weitz et al.

Summary: The study results showed that in knee arthroplasty patients receiving different doses of milvexian treatment, the incidence of venous thromboembolism with twice-daily dosing was significantly lower than the prespecified benchmark of 30%, with a lower risk of bleeding compared to enoxaparin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Hematology

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

Gary H. Lyman et al.

Summary: These evidence-based guidelines aim to support decision-making on the prevention and treatment of VTE in cancer patients, covering mechanical and pharmacological prophylaxis, as well as recommendations for initial, short-term, and long-term treatment based on patient risk and treatment circumstances. Recommendations vary depending on patient risk level and treatment situation.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Venous thromboembolism in cancer patients: a population-based cohort study

F. Mulder et al.

Summary: Over the past decade, the incidence of venous thromboembolism (VTE) in cancer patients may have changed due to novel cancer therapies, improved survival, and high-resolution imaging. The risk of VTE in cancer patients is steadily increasing and is ninefold higher than in the general population.

BLOOD (2021)

Add to Collection

Review Hematology

Factor XI as a Target for New Anticoagulants

James C. Fredenburgh et al.

Summary: The article discusses the rationale for developing factor XI inhibitors, identifies the most advanced stage agents, describes the results of completed clinical trials and ongoing trials, highlighting opportunities and challenges for this new generation of anticoagulants.

HAMOSTASEOLOGIE (2021)

Add to Collection

Article Hematology

Polyphosphate expression by cancer cell extracellular vesicles mediates binding of factor XII and contact activation

Young Jun Shim et al.

Summary: Extracellular vesicles (EV) play a role in promoting thrombosis in cancer by potentially activating the contact pathway of coagulation. EV derived from various cancer cell lines differ in their ability to activate FXII, with polyphosphate implicated in their prothrombotic effects.

BLOOD ADVANCES (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Factor XI Inhibition to Uncouple Thrombosis From Hemostasis JACC Review Topic of the Week

Charles Hsu et al.

Summary: Hemostasis and thrombosis are closely linked, with factor XI inhibitors potentially providing a safer alternative to current anticoagulants. Clinical studies are ongoing to determine the efficacy of factor XI inhibitors in attenuating thrombosis without disrupting hemostasis.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)

Add to Collection

Article Hematology

Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy

Tzu-Fei Wang et al.

Summary: This international registry study evaluated outcomes of patients receiving concurrent DOACs and targeted anticancer therapies, showing a higher incidence of bleeding compared to thrombosis, particularly with BTK inhibitors. Larger prospective studies are needed to further investigate these findings.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Abelacimab for Prevention of Venous Thromboembolism

Peter Verhamme et al.

Summary: Factor XI plays a significant role in the development of postoperative venous thromboembolism. Inhibition of Factor XI with a single intravenous dose of abelacimab after total knee arthroplasty was effective in preventing venous thromboembolism and had a low risk of bleeding.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

Nigel S. Key et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Hematology

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial

Robert D. McBane et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Medicine, General & Internal

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty The FOXTROT Randomized Clinical Trial

Jeffrey I. Weitz et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Review Hematology

Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis

Michela Giustozzi et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Medicine, General & Internal

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

Giancarlo Agnelli et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Hematology

Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials

Florian Moik et al.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Review Surgery

Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer

George Kirkilesis et al.

EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY (2019)

Add to Collection

Article Clinical Neurology

Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI

Benjamin Georgi et al.

STROKE (2019)

Add to Collection

Review Hematology

How I treat cancer-associated venous thromboembolism

Noemie Kraaijpoel et al.

BLOOD (2019)

Add to Collection

Article Oncology

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

Annie M. Young et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Gary E. Raskob et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

Patients' Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS)

Carme Font et al.

SUPPORTIVE CARE IN CANCER (2018)

Add to Collection

Article Economics

What Impact Does Venous Thromboembolism and Bleeding Have on Cancer Patients' Quality of Life?

Andrew J. Lloyd et al.

VALUE IN HEALTH (2018)

Add to Collection

Article Hematology

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

Noemie Kraaijpoel et al.

THROMBOSIS AND HAEMOSTASIS (2018)

Add to Collection

Article Hematology

Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events

Meir Preis et al.

BLOOD (2017)

Add to Collection

Review Hematology

Cancer-associated venous thromboembolism: Burden, mechanisms, and management

Cihan Ay et al.

THROMBOSIS AND HAEMOSTASIS (2017)

Add to Collection

Article Hematology

Epidemiology of first and recurrent venous thromboembolism in patients with active cancer A population-based cohort study

Alexander T. Cohen et al.

THROMBOSIS AND HAEMOSTASIS (2017)

Add to Collection

Article Hematology

Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis

Alok A. Khorana et al.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)

Add to Collection

Article Critical Care Medicine

Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report

Clive Kearon et al.

CHEST (2016)

Add to Collection

Article Medicine, General & Internal

Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer A Randomized Clinical Trial

Agnes Y. Y. Lee et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)

Add to Collection

Article Medicine, General & Internal

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

Harry R. Bueller et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study

Simon Noble et al.

PATIENT PREFERENCE AND ADHERENCE (2015)

Add to Collection

Article Hematology

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

N. van Es et al.

BLOOD (2014)

Add to Collection

Article Oncology

New Oral Anticoagulants and the Cancer Patient

Nicholas J. Short et al.

ONCOLOGIST (2014)

Add to Collection

Review Hematology

Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis

Marc Carrier et al.

THROMBOSIS RESEARCH (2014)

Add to Collection

Review Hematology

Epidemiology of cancer-associated venous thrombosis

Jasmijn F. Timp et al.

BLOOD (2013)

Add to Collection

Article Oncology

Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer

Linda Sharp et al.

PSYCHO-ONCOLOGY (2013)

Add to Collection

Article Hematology

Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis

Ophira Salomon et al.

THROMBOSIS AND HAEMOSTASIS (2011)

Add to Collection

Article Hematology

Reduced incidence of ischemic stroke in patients with severe factor XI deficiency

Ophira Salomon et al.

BLOOD (2008)

Add to Collection

Letter Hematology

Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy

A. A. Khorana et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)

Add to Collection

Article Medicine, General & Internal

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

AYY Lee et al.

NEW ENGLAND JOURNAL OF MEDICINE (2003)

Add to Collection

Article Hematology

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis

P Prandoni et al.

BLOOD (2002)

Add to Collection

Article Medicine, General & Internal

High levels of coagulation factor XI as a risk factor for venous thrombosis.

JCM Meijers et al.

NEW ENGLAND JOURNAL OF MEDICINE (2000)

Add to Collection

Article Medicine, General & Internal

Predictors of recurrence after deep vein thrombosis and pulmonary embolism -: A population-based cohort study

JA Heit et al.

ARCHIVES OF INTERNAL MEDICINE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.